Sofosbuvir
نویسندگان
چکیده
منابع مشابه
Sofosbuvir and daclatasvir
After entering hepatocytes, the viral genome of the hepatitis C virus (HCV) is translated into a single polypeptide. This polypeptide is subsequently cleaved into viral proteins, including non-structural (NS) proteins NS3, NS4A, NS5B and NS5B RNA dependent RNA polymerase (Figure 1) [3, 4]. These viral proteins are essential for viral replication and assembly making them significant targets for ...
متن کاملSofosbuvir-velpatasvir for treating chronic hepatitis C.
On Jan 25, 2017, the UK National Institute for Health and Care Excellence (NICE) published guidance recommending sofosbuvirvelpatasvir (Gilead Sciences Ltd, Uxbridge, UK) as an option for treating chronic hepatitis C in adults (table), only if the manufacturing company provides the drug with the price reduction in the simple discount agreement. NICE appraised sofosbuvirvelpatasvir as a single t...
متن کاملEnter Sofosbuvir: The Path to Curing HCV
The decision to leave the security of a large pharmaceutical company and jump into the unknown of a small biotech called Pharmasset with 15 staff members, limited capabilities, no labs, and little money would to many seem a foolish decision. In fact, many advised me to not make the move. But the desire and excitement to blaze a new trail where none had been, to build a research team where one b...
متن کاملEstimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
BACKGROUND As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. Th...
متن کاملCost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
UNLABELLED Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. A 24-week co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hospital Pharmacy
سال: 2014
ISSN: 0018-5787,1945-1253
DOI: 10.1310/hpj4905-466